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A B S T R A C T
Objective: To assess the degree of hypoxia and subjective dyspnea elicited by a 6-minute walking test
(6MWT) in COVID-19 patients prior to discharge.
Methods: A 6MWT was performed in 26 discharge-ready COVID-19 patients without chronic pulmonary
disease or cardiac failure. Heart rate, oxyhemoglobin saturation (SpO2), respiratory rate, and subjective
dyspnea measured on the Borg CR-10 scale were measured before and immediately after the 6MWT, with
continuous monitoring of SpO2 and heart rate during the 6MWT. The 6MWT was terminated if SpO2
dropped below 90%. A historical cohort of 204 patients with idiopathic pulmonary fibrosis (IPF) was used
for comparison.
Results: 13 (50%) of the COVID-19 patients developed exercise-induced hypoxia (SpO2 < 90%) during the
6MWT, of which one third had pulmonary embolism. COVID-19 patients experienced less hypoxia-
related dyspnea during the 6MWT compared with patients with IPF.
Conclusion: The 6MWT is a potential tool in the diagnosis of asymptomatic exercise-induced hypoxia in
hospitalized COVID-19 patients prior to discharge. Due to important methodological limitations, further
studies are needed to confirm our findings and to investigate their clinical consequences.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Anecdotal evidence is emerging that patients with COVID-19
may present with ‘silent hypoxia’, which refers to a discrepancy
between the level of hypoxia and subjective dyspnea experienced
by the patient (Couzin-Frankel, 2020). This phenomenon is of
potential concern among patients with chronically compromised
end-organ perfusion, for example in ischemic heart disease, where
the absence of dyspnea may permit an acute ischemic event to
progress to a critical level without the usual early warning
symptoms. We aimed to investigate whether silent hypoxia in
adult COVID-19 patients ready for discharge can be elicited by a
6-minute walking test (6MWT).
Patients hospitalized with COVID-19 confirmed by polymerase
chain reaction (PCR) testing at the University Hospital of* Corresponding author: Deparment of Infectious Diseases and Pulmonary
Medicine, University Hospital of Copenhagen, North Zealand, Denmark, Dureha-
vevej 29, 3400 Denmark.
E-mail address: zitta.barrella.harboe@regionh.dk (Z.B. Harboe).
https://doi.org/10.1016/j.ijid.2020.07.014
1201-9712/© 2020 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Copenhagen, North Zealand, Denmark were eligible for inclusion
at the time of planned discharge, which required resolution of
fever and an oxyhemoglobin saturation (SpO2) of 94% or above at
rest, without supplementary oxygen. Patients with chronic lung
diseases and New York Heart Association (NYHA) class II and above
were excluded. The 6MWT was carried out according to the
American Thoracic Society (ATS) statement from 2002 by trained
pulmonary physiotherapists (ATS Committee on Proficiency
Standards for Clinical Pulmonary Function Laboratories, 2002).
Patients were instructed to walk the greatest distance possible in 6
min, at a self-determined pace, pausing to rest if needed. Heart rate
(HR), SpO2, respiratory rate (RR), and dyspnoea rated between 1
and 10 on the Borg CR-10 dyspnea scale (Borg and Kaijser, 2006;
Borg, 1982) were recorded before and immediately after the
6MWT. A PaO2 below 80 mmHg (10.6 kPa) is generally considered
pathological, while a PaO2 of at least 60 mmHg (8 kPa), which
correlates to an SpO2 of 90%, is required to maintain sufficient
tissue oxygenation (Hansen et al., 1984). SpO2 and HR were
continuously monitored during the 6MWT. We assumed that
patients with no history of chronic lung disease should be able to
maintain an SpO2 of 96% or above, even during physical activityciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Baseline characteristics of 26 patients with COVID-19 undergoing the 6-minute walking test (6MWT) at hospital discharge and a historical cohort of 204 patients with
idiopathic pulmonary fibrosis who underwent the same test.
COVID-19 patients IPF patients (n = 204)
Total number of
patients (n = 26)
6-MWT completed
(n = 13)
6-MWT terminated early due to
SpO2 < 90% (n = 13)
Age in years, median (range) 63 (29–85) 62 (29–85) 64 (38–76) 74 (42–92)
Male sex, n (%) 16 8 (62) 8 (62) 158 (77)
Number of comorbidities per patient, median (range) 1 (1–5) 1 (1–5) 1 (1–4) Unknown
Need for ICU during admission, n (%) 8 (31) 2 (15) 6 (46) Unknown
Need for mechanical ventilation during admission, n (%) 2 (15) 0 (0) 2 (15) Unknown
Infiltrate on chest X-ray during admission, n (%) 21 (81) 8 (62) 13 (100) Unknown
Figure 1. Decline in oxygen saturation (SpO2) and Borg CR-10 dyspnea scale rating
after 6MWT in patients with COVID-19 (blue) and idiopathic pulmonary fibrosis
(red). Each dot represents one patient. The lines are based on univariate linear
regression.
N.J.U. Fuglebjerg et al. / International Journal of Infectious Diseases 99 (2020) 100–101 101(Casanova et al., 2011). A previous prospective cohort of 204
patients with idiopathic pulmonary fibrosis (IPF), who also
underwent the 6MWT according to the ATS guidelines, was used
for comparison (Hoyer et al., 2019).
Forty-seven consecutive patients were screened between April
16 and April 28, 2020, and all 26 eligible patients without exclusion
criteria were included. The 6MWT was terminated early in 13
patients (50%) due to an SpO2 below 90%. Baseline characteristics
in patients who terminated the 6MWT early compared with those
who completed the 6MWT, as well as baseline characteristics for
the comparison group, are presented in Table 1. COVID-19 patients
with an SpO2 below 90% during the 6MWT had only discrete
increase in perceived dyspnea (Figure 1). Six patients who
terminated the 6MWT early due to hypoxia were investigated
with CT angiography and/or ventilation-perfusion scintigraphy in
order to exclude pulmonary embolism (PE), which was confirmed
in four patients. As a comparison group, IPF patients had a similar
decline in SpO2, but they developed more pronounced concomi-
tant worsening in the level of subjective dyspnea measured by the
Borg scale (Figure 1). COVID-19 patients had a mean peak score of
2.5 on Borg CR-10 (range 0–5) during the 6MWT, compared with
4.1 (range 0–10) in IPF patients.
In summary, nearly half of hospitalized COVID-19 patients
without chronic pulmonary disease developed marked exercise-
induced hypoxia without accompanying subjective dyspnea at the
time of discharge, and one third of patients who terminated the
6MWT early had PE. We interpret this as evidence of silent hypoxia.
Our study had several limitations. No previous studies have
examined the role of the 6MWT in otherwise healthy adults with
COVID-19 or other acute respiratory tract infections, although
exercise-induced hypoxia has been used in the diagnosis
and severity assessment of Pneumocystis jirovecii pneumonia inHIV-positive adults (Sauleda et al., 1994). Clinical implications of
this hypoxia are thus not well described, and we therefore decided
to routinely terminate the 6MWT early if SpO2 dropped below 90%
for safety reasons. This could have led to underestimation of the
relative degree of dyspnea in COVID-19 patients, since they were
compared with a control group of IPF patients, who were all
allowed to complete the 6MWT unless they developed chest pain,
intolerable dyspnea, leg cramps, staggering, diaphoresis, or pale or
ashen appearance, in accordance with the ATS guidelines.
Furthermore, patients in our control group all had IPF, a condition
resulting in hypoxic respiratory failure, and therefore increased
tolerance to lower SpO2 without subjective dyspnea was a
possibility in this group.
We propose further, larger studies to confirm our findings using
a more accurately matched prospective group of controls, and to
investigate the clinical consequences of silent hypoxia in particular
among patients at elevated risk of serious end-organ ischemic
events after discharge to the community.
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